كندا - الإنجليزية - Health Canada

abbvie corporation - upadacitinib - tablet (extended-release) - 15mg - upadacitinib 15mg - disease-modifying antirheumatic agents

كندا - الإنجليزية - Health Canada

abbvie corporation - upadacitinib - tablet (extended-release) - 30mg - upadacitinib 30mg - disease-modifying antirheumatic agents

كندا - الإنجليزية - Health Canada

abbvie corporation - upadacitinib - tablet (extended-release) - 45mg - upadacitinib 45mg

إسرائيل - الإنجليزية - Ministry of Health

abbvie biopharmaceuticals ltd, israel - upadacitinib as hemihydrate - tablets prolonged release - upadacitinib as hemihydrate 45 mg - upadacitinib - ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

ماليزيا - الإنجليزية - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

abbvie sdn bhd - upadacitinib hemihydrate -

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

abbvie limited - upadacitinib hemihydrate 15.4mg equivalent to upadacitinib 15mg - modified release tablet - 15 mg - active: upadacitinib hemihydrate 15.4mg equivalent to upadacitinib 15mg excipient: colloidal silicon dioxide hypromellose magnesium stearate mannitol microcrystalline cellulose opadry purple 85f100091 tartaric acid - rinvoq is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis. rinvoq may be used as monotherapy or in combination with methotrexate or other conventional synthetic disease modifying anti-rheumatic drugs (csdmards).

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

abbvie limited - upadacitinib hemihydrate 30.7mg equivalent to upadacitinib 30 mg - modified release tablet - 30 mg - active: upadacitinib hemihydrate 30.7mg equivalent to upadacitinib 30 mg excipient: colloidal silicon dioxide hypromellose magnesium stearate mannitol microcrystalline cellulose opadry red 85f150093 tartaric acid - rinvoq is indicated for the treatment of adults and adolescents 12 years and older with moderate to severe atopic dermatitis who are candidates for systemic therapy.

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

abbvie limited - upadacitinib hemihydrate 46.1mg equivalent to upadacitinib 45 mg - modified release tablet - 45 mg - active: upadacitinib hemihydrate 46.1mg equivalent to upadacitinib 45 mg excipient: colloidal silicon dioxide hypromellose magnesium stearate mannitol microcrystalline cellulose opadry yellow 85f120063 tartaric acid - rinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

ماليزيا - الإنجليزية - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pfizer (malaysia) sdn. bhd. - lorlatinib -

المملكة المتحدة - الإنجليزية - MHRA (Medicines & Healthcare Products Regulatory Agency)

wyeth pharmaceuticals - not applicable